Accretion Pharmaceuticals results, half year to Mar 2026
NSE: ACCPLPharmaceuticals & Biotechnology
Accretion Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2025 · Issue price ₹101
Last close ₹185.00₹0.00 (0.00%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹185.00.
28 Oct: open ₹181.95, high ₹185.00, low ₹181.95
52-week range of traded prices to 28 Oct 2026
₹54.60Low, 7 Nov 2025₹220.00High, 30 Sep 2026
- Next results date: the board meets on 31 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹206 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.27
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,800100.0% delivered
Accretion Pharmaceuticals filed its results for the half year to Mar 2026 on 8 May 2026 at 7:35 pm, standalone: the listed company alone, without its subsidiaries.
Results for the half year to Mar 2026
₹ crore.Accretion Pharmaceuticals annual results and balance sheet
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹46 Cr+18.2% on a year ago · +4.9% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- ₹4.92 Cr+13.5% on a year ago · +3.4% on the half year before
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- ₹4.42−16.6% on a year ago · −4.1% on the half year before
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.7%
From revenue to net profit, ₹ crore
- Revenue46
- Other income+0.1
- Finance costs−0.5
- Profit before tax6.7
- Tax−1.8
- Net profit4.9
Accretion Pharmaceuticals results by half year
Standalone: the listed company alone, without its subsidiaries. Latest half year to Mar 2026. Results for the half year to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date
Revenue and net profit by half year, ₹ crore
- Revenue
- Net profit
Peak revenue ₹46 Cr, half year to Mar 2026; lowest ₹19 Cr, half year to Sep 2024
Operating and net margin by half year, per cent
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- Net margin
| ₹ crore | Sep 2024worked out | Mar 2025Filed 11 Jun | Sep 2025Filed 14 Nov | Mar 2026Filed 8 May |
|---|---|---|---|---|
| Revenue from operations | 18.6what Revenue from operations, Sep 2024, includes. Not filed on its own: worked out as the year to Mar 2025 the company filed, less the six months to Mar 2025. | 38.8 | 43.7 | 45.9 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | – | – | 36.7 | – |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 12.0 | 27.9 | 32.2 | 33.0 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | – | – | 2.1 | – |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | – | – | 2.5 | – |
| Operating profit before depreciationOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary | – | – | 7.1 | – |
| Operating margin | – | – | 16.2% | – |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | – | – | 0.4 | – |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 0.0 | 0.1 | 0.1 | 0.1 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 0.7 | 0.7 | 0.4 | 0.5 |
| Profit before tax | 3.3 | 6.5 | 6.4 | 6.7 |
| 0.8 | 2.1 | 1.7 | 1.8 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | 25.2% | 33.1% | 25.9% | 26.3% |
| Net profit | 2.5 | 4.3 | 4.8 | 4.9 |
| Net margin | 13.3% | 11.2% | 10.9% | 10.7% |
| Earnings per share | – | ₹5.30 | ₹4.61 | ₹4.42 |
Earnings per share in rupees, restated for later splits and bonuses.